Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

NCT07102394 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.

NCT NCT07102394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07102394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Lead sponsor
Johns Hopkins University
Phase
Phase 1
Overall status
Recruiting
Start date
February 1, 2026
Completion date
December 31, 2027
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous neurofibroma, neurofibroma, neurofibromas, neurofibromatosis, nf1, von recklinghausen disease